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High dose chemotherapy in light chain or light and heavy chain
deposition disease.
Background. Conventional chemotherapy for myeloma yield
unsatisfactory results in light and/or heavy chain deposition dis-
ease [(H)CDD] Because of the well-established dose-response
effect of high dose melphalan in multiple myeloma, aiming to
dramatically reduce the pathogenic monoclonal immunoglob-
ulin (MIg) level, high dose therapy is a tempting alternative
approach.
Methods. We treated 11 young patients with L(H)CDD by
high dose therapy with the support of autologous blood stem
cell transplantation. All had renal symptoms, including four who
required dialysis and seven who had various, mainly cardiac,
extrarenal manifestations.
Results. No toxic deaths occurred. A decrease in the MIg
level was observed in eight patients, with complete disappear-
ance from serum and urine in six cases. Improvement in mani-
festations related to MIg deposits were observed in six patients,
including renal, cardiac, and hepatic responses in 4/11, 4/4, and
2/2 cases, respectively. Histologic regression of MIg deposits was
documented in cardiac, hepatic, and skin biopsies. In contrast,
examination of the kidney still showed light chain deposits in
one patient who had renal transplantation 3 years after high
dose therapy, at a time when he was in persisting remission.
Within a median follow-up of 51 months, three patients were
retreated because of multiple myeloma relapse, of whom one
died and one required hemodialysis, and renal function sec-
ondarily deteriorated in a patient who had resistant multiple
myeloma. Otherwise, no manifestations related to MIg deposits
occurred or recurred in any patient.
Conclusion. Present results of this retrospective study argue
in favor of a benefit of high dose therapy with stem cell support
in young patients with L(H)CDD.
Monoclonal immunoglobulin (MIg) deposition in tis-
sue may occur either as Congo red binding fibrils, in
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AL amyloidosis, or as amorphous, nonfibrillar deposits in
light and/or heavy chain deposition diseases [L(H)CDD]
[1]. First reported in 1973 [abstract; Antonovych T,
et al, Lab Invest 30:370A, 1974], L(H)CDD was definitely
characterized in 1976 by Randall et al [2] who recognized
the systemic nature of the disease. Renal involvement
is a constant feature of L(H)CDD and renal manifesta-
tions often dominates the clinical presentation. Protein-
uria is often an early finding, rapidly followed by renal
failure, the high prevalence, early appearance, and sever-
ity of which is remarkable [3]. In addition to the kidney,
light and/or heavy chain [L(H)C] deposition may involve
other organs, particularly the heart and the liver where
it can be totally asymptomatic or cause life-threatening
damage. This explains, at least in part, why the survival
time from onset of symptoms varies from a few months to
10 years [4].
L(H)CDD results from the deposition of monotypic
immunoglobulin (Ig) chains along basement membranes.
Nodular glomerulosclerosis is the most characteristic
pathologic renal feature. Immunofluorescence examina-
tion is a key step in the diagnosis, showing monotypic
deposition of light chain (or heavy chain) along glomeru-
lar and, more important, tubular basement membranes
[3]. Monotypic Ig chains are produced by a monoclonal
B-cell clone, the burden of which may be variable. It may
be associated with multiple myeloma or other lympho-
proliferative disease, but many patients have no evidence
of any overt plasma cell dyscrasia and the presence of a
serum or urine monoclonal Ig component cannot be es-
tablished in some of them [1, 4].
Even in the latter cases, present treatment is based
on eliminating the clonal plasma cells responsible for
the production of the deposited protein. Using con-
ventional chemotherapy, this approach benefits only a
minority of patients [4]. Because of the well-established
dose-response effect of melphalan in myeloma patients
[5], high dose therapy is an alternative tempting ap-
proach, although it appears challenging owing to the renal
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and cardiac dysfunction that commonly occurs in patients
with L(H)CDD. However, recent advances in supportive
care and the availability of growth factors and mobilized
stem cells have reduced the morbidity and mortality of
high dose therapy, including in patients with renal dys-
function [6, 7]. This prompted us to attempt high dose
therapy, with the support of autologous stem cell trans-
plantation, in patients with L(H)CDD. We report our ex-
perience of this therapeutic approach in 11 patients.
METHODS
We retrospectively reviewed all patients with
L(H)CDD who were treated by high dose therapy and
autotransplantation in our department. The first (N = 4)
were treated in the early 1990s with encouraging results,
particularly in one case [8]. Therefore, since 1995, we
decided to treat by high dose therapy all patients with
L(H)CDD, whatever their renal function, provided
they were under 65 years of age, had a relatively good
performance status (OMS index ≤ 2) and gave informed
consent. Between 1995 and 1999, we saw seven patients
who met these criteria. All were included in this study,
in addition to the initial four.
In all 11 patients, L(H)CDD was diagnosed by means
of renal biopsy, according to accepted criteria, includ-
ing immunofluorescence data demonstrating nonamyloid
monotypic light chain and/or heavy chain deposition in
renal parenchyma, particularly along tubular basement
membranes [3]. Specific stainings for amyloid deposits
were performed in all cases.
Serum and urine protein immunofixation (or immuno-
electrophoresis), skeletal x-ray films and at least one bone
marrow aspiration were performed in all patients. The di-
agnosis of multiple myeloma was considered when at least
5% of unequivocally dystrophic plasma cells were seen
on bone marrow smears and/or when obvious lytic bone
lesions were detected on x-ray films. Multiple myeloma
stages were defined according to the Durie and Salmon
staging system [9]. Briefly, stage I was characterized by
relatively low monoclonal protein serum and urine con-
centrations, normal calcemia, and absence of anemia and
of bone lesions. Stage III multiple myeloma was consid-
ered when multiple bone lesions, high monoclonal pro-
tein concentration, hypercalcemia, and/or a hemoglobin
serum level of less than 10 g/dL were observed. Patients
who do not fulfill the criteria for stage I or stage III were
classified as stage II. In the absence of these abnormali-
ties and of more than 5% of dystrophic plasma cells on
bone marrow smears, patients were considered to have a
monoclonal gammopathy of undetermined significance,
although atypical because of the MIg deposit-related or-
gan manifestations (“MGUS”).
TREATMENT
In all cases, autologous blood stem cells (ABSC) were
collected at diagnosis. The mobilization procedure and
subsequent therapeutic protocol varied according to the
period of time (before and after 1995).
In the four patients treated before 1995, ABSC were
mobilized by chemotherapy alone (cyclophosphamide
4 g/m2). Thereafter, patients received three to six
monthly courses of a standard dose chemotherapeutic
regimen, most often a vincristine, adriblaotine, dexam-
ethasone (VAD)-like regimen [combining continuous
24-hour-infusion of vincristine (0.4 mg/day) and dox-
orubicin (9 mg/m2/day) with intravenous methylpred-
nisolone (400 mg/day) for 4 days]. In three cases, high
dose therapy was performed according to a previously
described protocol combining melphalan 140 mg/m2, cy-
clophosphamide 60 mg/kg, CCNU and VP16 with a 12
gray total body irradiation (TBI) [10]. The last patient
did not receive TBI but a combination of melphalan
140 mg/m2 (given as a single 2-hour perfusion) and oral
busulfan (4 mg/kg/day × 3 days).
In the seven following patients, ABSC mobilization
was performed using granulocyte-colony-stimulating fac-
tor (G-CSF) (10 lg/kg/day × 4 days). For these seven
patients, no standard dose chemotherapy was adminis-
tered between ABSC collection and high dose therapy.
Pretransplant cytoreduction used high dose melphalan
alone (140 mg/m2 (N = 6) or 200 mg/m2 (N = 1) given as
a single 2-hour perfusion on day 2). Two tandem courses
of melphalan 140 mg/m2 separated by 3 to 5 months were
performed in two patients. ABSC were reinfused at day
0 and all patients received G-CSF (5 lg/kg/day) from day
6 posttransplant until the absolute neutrophil count was
greater than 1.0 × 109/L.
In all cases, graft content of hematopoietic progenitors
was assessed numerating CD34-positive cells. All high
dose therapy regimens were supported by the reinfusion
of at least 2 × 106/kg CD34-positive cells. High dose
therapy and autotransplantation were performed in a
protected unit. Supportive care was given as needed and
included blood products and broad-spectrum antibiotics.
Patients requiring renal replacement therapy were dia-
lyzed prior to high dose melphalan infusion and then
72 hours later; otherwise, their hemodialysis schedule was
unchanged, at three times a week throughout the trans-
plant period.
The response to treatment was monitored clinically
and by means of serum and urine immunoglobulin stud-
ies. Complete immunochemical remission was defined
by the disappearance of MIg on immunofixation studies
of serum and urine. A very good response was consid-
ered when a reduction of 75% or more in the MIg level
was observed. Improvement in clinical manifestations re-
lated to L(H)C deposits was assessed on the basis of the
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Table 1. Patients’ characteristics at beginning of treatment
Number of patients 11
Median age years (range) 42 (35–65)
Sex M/F 7/4
Clinical manifestations
Nephrotic syndrome 3
Renal insufficiencya
Creatinine > 200 lmol/L 5
Dialysis 4
Congestive heart failure 4
Hepatomegaly + cholestasis 2
Neurologic symptoms and endocrinopathyb 1
Number of organs involved
<2 clinical manifestations 4
=2 clinical manifestations 5
≥3 clinical manifestations 2
Monoclonal protein
IgG j 3
IgG k 1
IgD k 1
Light chain j only 5
None 1
Myeloma 10
Stage I 7
Stage III 3
“MGUS” 1
Median time from diagnosis to ABSCT months (range) 7 (3–48)
ABSCT is autologous blood stem cell transplant.
aTwo patients received transient dialysis during ABSCT mobilization.
bFacial palsy, hyperproteinorachia, pan-hypopituitarism.
following criteria adapted from those described by Gertz
et al in AL amyloidosis [11]: resolution of symptoms of
congestive heart failure with improved echocardiogra-
phy; reduction in the size of the liver by more than 2 cm
(with normalization of serum alkaline phosphatase); im-
provement in renal function; and at least a 50% decrease
in the 24-hour urinary protein excretion associated with
a serum albumin level reincrease, in the absence of pro-
gressive renal insufficiency, in patients presenting with
the nephrotic syndrome.
RESULTS
Patients’ characteristics
Table 1 summarizes the main data from the 11 patients.
There were four women and seven men. Their median age
was 42 years (range 35 to 65 years). Median time from first
symptoms to high dose therapy was 7 months (range 3 to
48 months).
At presentation, all patients had renal symptoms,
mostly proteinuria and renal failure. Proteinuria was
found in ten patients, including three with nephrotic
syndrome (urine protein >3 g/day and serum albumin
<30 g/L). Renal failure was present in nine patients
of whom four experienced rapid deterioration of re-
nal function and required definitive dialysis. The five
other patients initially had mild renal insufficiency
with serum creatinine levels ranging between 170 and
300 lmol/L.
Extrarenal manifestations were cardiac (N = 7), hep-
atic (N = 2), and neurologic (N = 1). Five patients
had two involved organs and two patients had three
or more involved organs. The two patients with symp-
toms due to liver deposits had hepatomegaly and mild
increase in serum alkaline phosphatase level. Heart in-
volvement dominated the clinical presentation in four
patients who had congestive heart failure in combina-
tion with echocardiographic signs suggestive of Ig de-
posits (increased thickness of interventricular septum,
abnormal myocardial texture, and decreased systolic ven-
tricular function). In three other patients, of whom two
experienced arrhythmia episodes and one had no cardiac
symptoms, ultrasound examination of the heart showed
abnormalities suggestive of cardiac deposits. One patient
had central nervous system manifestations, including fa-
cial palsy and endocrine dysfunction of central origin
(hypothyroidism, adrenal insufficiency, diabetes in-
sipidus, and hypogonadism). In addition, the patient had
a massive protein increase in cerebrospinal fluid (8 g/L
containing monoclonal j light chain) without associated
hypercellularity.
Light microscopy and immunofluorescence studies of
renal biopsies showed glomerular and tubular lesions
characteristic of L(H)CDD in all patients. Nine had only
light chain deposits with predominance of j isotype (N =
7) as compared to k isotype (N = 2). In the two remaining
patients, deposits were composed of j light chain associ-
ated with c heavy chain. In one case, a typical pattern
of jLCDD was combined with small Congo red–positive
deposits.
In the two patients with symptomatic liver involve-
ment, hepatic biopsy showed light chain deposits con-
fined to sinusoids and basement membranes of biliary
ductules without associated parenchymal lesions. Two
patients, one with heart failure and the other with
nonsymptomatic echocardiographic abnormalities, had
myocardial biopsy showing monotypic deposits in the
vascular walls and perivascular areas of the heart. Im-
munofluorescence studies of skin biopsy samples were
performed in nine patients and disclosed monotypic Ig
deposits of variable localization, most often at the der-
moepidermal junction, in six cases. Congo red staining
was negative in all cases except in that patient with both
renal jLCDD and amyloidosis in whom cutaneous stud-
ies also suggested the combination of the two types of
deposits.
A monoclonal Ig was detected in the serum and/or
urine of ten patients. Isotypes were IgGj (N = 3), IgGk
(N = 1), IgDk (N = 1), and j light chain only (N = 5). One
patient with j light chain renal deposits and hypogamma-
globulinemia had no monoclonal Ig detectable in serum
and urine. Ten patients had overt multiple myeloma,
seven of whom had stage I disease and three had stage III
disease, according to the Durie and Salmon classification.
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Table 2. After high dose therapy visceral improvement in patients in complete (or near complete) response
Kidneya Heart Miscellaneous Outcome
1 Still requiring dialysis Improvedb Improvement in liverc and neurologic
manifestationsd
Alive (36 months +)
Relapse (24 months)
2 Still requiring dialysis No more arrhythmic
Episodes
Alive in CR (25 months +)
3 Resolution of nephrotic syndrome;
creatinine level (300 → 160 lmol/L)
Improvedb,e Improvement in hepatic manifestationsc,e Relapse (44 months)
Dead (85 months)
4 Renal transplant (36 months after high
dose therapy)
Alive in CR (50 months)
5 Creatinine level (250 → 80 lmol/L) Improvedb Alive (88 months +)
Relapse (30 months)
Dialysis (74 months)
6 Resolution of nephrotic syndrome;
creatinine level (260 → 110 lmol/L)
Improvedb Alive in CR (65 months +)
CR is complete remission.
aSee also Table 3.
bResolution of symptoms of congestive heart failure with improved echocardiography.
cReduction in the size of the liver by more than 2 cm (with normalization of serum alkaline phosphatase).
dImproved in facial palsy and encephalopathy, decrease in cerebrospinal fluid level protein.
eHistological regression of L(H)C deposits.
Treatment and treatment-related toxicity
All patients in whom ABSC were mobilized using
chemotherapy had febrile neutropenia. Two of these,
who at presentation had a serum creatinine level of
80 and 250 lmol/L, experienced acute renal failure
during bacterial sepsis complicating the chemotherapy-
induced aplasia. Both required transient dialysis for 1 and
12 weeks, respectively. When performed after G-CSF
alone, ABSC mobilization and collection were well toler-
ated. A single mobilization procedure, followed by one to
four leukaphereses, allowed to collect an adequate num-
ber of CD34-positive cells in all patients but one, who had
to be mobilized twice.
No toxic death occurred either during ABSC mobi-
lization and collection or during high dose therapy and
auto-transplantation. Three of the four patients who re-
ceived high dose mephalan while on hemodialysis de-
veloped cerebral and/or cardiac complications. Two had
episodes of atrial fibrillation and two developed severe
encephalopathy with generalized tonic-clonic seizures
and coma, one of these after treatment by mephalan
200 mg/m2. In both, causes of coma such as infections,
metabolic disturbances, cerebral ischemia, or hemor-
rhage were excluded. Both patients recovered but me-
chanical ventilation was needed for 2 weeks in the one
who had central nervous system involvement due to
LCDD. In contrast, one hemodialyzed patient received
sequential high dose therapy and tandem transplant with
no significant complications.
Two of the seven patients with no or mild renal insuffi-
ciency pretransplant developed transient moderate dete-
rioration of renal function during the aplasia consecutive
to high dose therapy. Hematopoietic recovery was satis-
factory in all patients, with a median number of 13 and
14 days to reach more than 1 × 109/L granulocytes and
more than 25 × 109 platelets, respectively. These features
were similar in patients with or without end-stage renal
failure. All patients returned home within a median time
of 18 days (range 13 to 130 days) after transplantation.
Response to therapy
High dose therapy and autotransplantation produced
a decrease in the level of MIg in eight of the ten patients
who initially had a detectable monoclonal gammopathy.
Six patients (four of seven and two of three with stage I
and stage III multiple myeloma, respectively) achieved
complete immunochemical remission and two patients
were considered very good responders.
Improvement in manifestations related to L(H)C de-
posits were observed in six patients, five of whom had
achieved a complete immunologic response and one a
very good one (Table 2). According to previously de-
scribed criteria, cardiac, hepatic, and renal responses
were observed in four of four, two of two, and four of
11 cases, respectively. In addition, a neurologic response
occurred in one patient.
All four patients who initially had congestive heart
failure had resolution of clinical symptoms of heart in-
volvement, complete in three of them. Echocardiogram
improved in five of the seven cases with initial abnormal-
ities and the two patients who had arrhythmic episodes
did not experience recurrence. Reduction in the size of
the liver by more than 2 cm and normalization of serum
alkaline phosphatase was observed in the two patients
with hepatic manifestations. The patient with neurologic
and endocrine symptoms experienced a marked improve-
ment in facial palsy and encephalopathy, associated with
a decrease in cerebrospinal fluid protein level (from 8 g/L
at transplantation to 1 g/L 3 months posttransplant), but
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Table 3. Renal response 1 year after high dose therapy (HDT)
Serum creatinine Proteinuria
lmol/L Hemodialysis Serum albumin g/L g/24 hours
Pre-HDT Post-HDT Pre-HDT Post-HDT Pre-HDT Post-HDT Pre-HDT Post-HDT
1a — — Yes Yes 42 45 — —
2a — — Yes Yes 40 40 — —
3a 300 160 — — 28 39 4 0.2
4a — — Yesb Yesb 44 48 — —
5a 250 80 Transient No 35 38 12 0.15
6a 280 110 Transient No 25 38 5 1.5
7 250 250 — — 49 49 2 2
8 80 80 — — 30 37 3 2.5
9 170 170 — — 38 40 0.25 0.3
10 170 90 — — 44 45 4 0.2
11 — — Yes Yes 42 44 — —
aPatients in complete immunologic remission.
bPatient 4 underwent renal transplantation 36 months after high dose therapy.
no improvement in endocrine dysfunction. In the seven
patients who died, not needing permanent dialysis, six
had an increased creatinine level before high dose ther-
apy; the creatinine was unchanged in two and improved
by 50% to 75% 1 year posttherapy in four. The nephrotic
syndrome disappeared in three of three patients (see
Tables 2 and 3).
Histologic regression of L(H)C deposits was docu-
mented in the cardiac (N = 1) and hepatic (N = 1) biop-
sies performed 1 year after high dose therapy. In addition,
complete disappearance of skin L(H)C deposits was ob-
served in four of the five patients in whom immunoflu-
orescence studies on skin biopsy samples were repeated
(Fig. 1). Of note, in the patient with both LCDD and AL
amyloidosis, immunofluorescence studies became nega-
tive whereas Congo red staining of skin samples remained
positive. In contrast, examination of the kidney showed
light chain deposits in one patient with end-stage renal
failure who achieved a complete immunochemical remis-
sion and had nephrectomy 3 years after high dose therapy.
The kidney ablation was performed during renal trans-
plantation, at a time when there was no evidence for re-
currence either of monoclonal gammapathy (including
no abnormal plasma cells on bone marrow smears) or of
extrarenal deposits.
Patients’ outcome
Within a median follow-up of 51 months (14 to 129
months) since high dose therapy, two of the three
patients with stage III and one patient with stage I
multiple myeloma relapsed and were retreated by con-
ventional chemotherapy 30, 40, and 24 months posttrans-
plant, respectively. Otherwise, without any maintenance
treatment, no patient developed a symptomatic multiple
myeloma or modification of Ig levels.
No extrarenal manifestations related to Ig deposits
occurred or recurred in any patient, including in those
who did not achieve an immunologic response and in the
patients in whom multiple myeloma relapsed. Similarly,
nephrotic syndrome did not appear or re-appear in any
patient. Renal function secondarily deteriorated in one
patient with relapsing multiple myeloma who required
hemodialysis 74 months posttransplant. Another patient,
who had resistant stage I multiple myeloma, experienced
secondary deterioration of renal function with a 75% in-
crease in serum creatinine level (from 170 to 250 lmol/L)
during the fourth year posttransplant.
During follow-up, only one patient died, 93 months
posttransplant, because of progressive myeloma. At anal-
ysis, four patients required hemodialysis. The remaining
patients, including one who underwent successful renal
transplantation, had a serum creatinine level ranging be-
tween 100 and 250 lmol/L.
DISCUSSION
Until recently, very few patients with L(H)CDD have
been treated by high dose therapy [8, 12]. Taking benefit
of the growing experience of high dose therapy with stem
cell support in patients with myeloma or AL amyloido-
sis, including those with renal failure (6, 7, 13, 14), we
decided to use this therapeutic approach in all patients
with L(H)CDD, provided they were under 65 years of
age, had a relatively good performance status, and gave
informed consent. Since 1990, all patients seen in our de-
partment and fulfilling these criteria were included in the
present series.
In addition to the feasibility of high dose therapy with
autologous blood stem cell support, this series docu-
ments its safety in patients with L(H)CDD. Indeed, al-
though all patients presented with symptomatic renal and
extrarenal manifestations typical of L(H)CDD [3, 15],
including three with end-stage renal failure, three with
symptomatic heart involvement, and one with both, no
toxic death occurred either during ABSC mobilization
or during high dose therapy and autotransplantation.
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Fig. 1. Immunofluorescence study on unin-
volved skin of one patient. At diagnosis, de-
posits of IgG (A), and j light chain (B) on the
elastic fibers at the dermoepidermal junction
and around vessels, absence of k light chain
deposits (C). One year after autologous blood
stem cell transplant, there is an absence of IgG
deposits (D).
Moreover, no durable treatment-related deterioration of
renal function occurred in any patient and the morbid-
ity of the procedure was usually acceptable, particularly
when stem cells were mobilized by G-CSF alone and
when transplant cytoreduction used high dose melphalan
alone. Of note, however, two patients with end-stage re-
nal failure developed severe encephalopathy, which may
be related to high dose melphalan [16]. In one of these, the
dose of melphalan was 200 mg/m2; we no longer use this
dosage in patients on hemodialysis even though melpha-
lan pharmacokinetics has been reported to be normal in
case of renal insufficiency [17]. In the other patient, who
received 140 mg/m2 of melphalan, encephalopathy was
likely favored by central nervous system involvement,
which is unusual in L(H)CDD but was observed by Ran-
dall et al in their princeps case [2].
This series also demonstrates that high dose therapy,
effecting a high immunologic response rate with marked
or complete suppression of the pathogenic MIg, often
results in stabilization and even regression of L(H)C de-
posits with subsequent improvement in function of in-
volved organs. This was particularly significant in the four
patients with congestive heart failure who experienced
impressive clinical and echocardiographic improvement
and in the three patients with the nephrotic syndrome
who achieved a major renal response. Importantly, histo-
logic evidence for regression of L(H)C deposits was ob-
tained in heart, liver, and skin. In addition, most responses
were durable and, within a median follow-up of 50 months
after high dose therapy, only one renal death and one
patient death were observed, both when the underlying
multiple myeloma had relapsed. These results com-
pare favorably with those of conventional chemotherapy
which rarely improves extrarenal manifestations due to
L(H)C deposition and may benefit only some patients
with moderate impairment of renal function [15, 18, 19].
Indeed, in 18 patients treated by conventional chemother-
apy, Pozzi et al [18] observed worsening in renal function
and development or extension of extrarenal symptoms in
11 and 7 patients, respectively. In the other main series
of conventionally treated patients (N = 19), 5-year sur-
vival free of end-stage renal disease was 37% and 82%
of the patients who initially had a serum creatinine con-
centration over 350 lmol/L progressed to end-stage renal
disease despite therapy [19].
Recent reports of patients with AL amyloidosis treated
by high dose therapy with stem cell support also docu-
ment objective response with regression of amyloid de-
posits but underline the high morbidity and mortality
of the treatment in these patients [11, 20, 21]. The in-
cidence of toxic reactions, resulting in death rates up
to 43% [20], far exceeds the rate of treatment-related
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complications we have seen in high dose therapy for
L(H)CDD. This difference may be due, at least in part,
to the gastrointestinal tract toxicity of high dose ther-
apy, which is much more marked in patients with AL
amyloidosis than in those with L(H)CDD. In the for-
mer, amyloid infiltration of submucosal vessels in the
bowel frequently causes gastrointestinal tract bleeding
or perforation which may precipitate multiorgan failure
[11], whereas gastrointestinal tract L(H)C deposits, if any,
rarely produce complications.
Albeit involving a small number of patients, the present
retrospective study argues in favor of high dose therapy
with stem cell support in young patients with L(H)CDD.
This treatment may improve renal and extrarenal mani-
festations due to L(H)C deposits and may prevent their
progression without resulting in excessive morbidity or
mortality, including in patients with severe organ failure.
Moreover, as illustrated by one of our patients, those with
end-stage renal disease may achieve immunologic and
extrarenal remissions good enough to be subsequently
proposed for renal transplantation.
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